Humm J L
J Nucl Med. 1986 Sep;27(9):1490-7.
Radioimmunotherapy (RIT) is rapidly attracting interest as a potential new weapon in the arsenal for cancer therapy. This article concentrates on some of the dosimetric aspects affecting the potential success of RIT, and examines factors which influence the choice of a radiolabel for RIT. No radionuclide is likely to give an optimum tumor/nontumor insult for all tumor types; therefore, the concept of matching the source to tumor morphology is introduced. Lists of candidate radionuclides are given, classified according to the type of decay, range, and energy of the emission. The article examines how the choice of radionuclide for radiolabeling the antibody affects the local energy deposition in the tumor. Both the effect of tumor size on the energy absorbed fraction and the problem of antibody binding heterogeneity are discussed. The approach to RIT is to relate the choice of radionuclide to the physical properties of the tumor.
放射免疫疗法（RIT）作为癌症治疗武器库中的一种潜在新武器，正迅速引起人们的关注。本文着重探讨影响RIT潜在成功的一些剂量学方面，并研究影响RIT放射性标记选择的因素。没有一种放射性核素可能对所有肿瘤类型都能提供最佳的肿瘤/非肿瘤损伤；因此，引入了使放射源与肿瘤形态相匹配的概念。给出了候选放射性核素列表，并根据衰变类型、发射范围和能量进行分类。本文研究了用于标记抗体的放射性核素选择如何影响肿瘤内的局部能量沉积。讨论了肿瘤大小对能量吸收分数的影响以及抗体结合异质性问题。RIT的方法是将放射性核素的选择与肿瘤的物理特性联系起来。
